| Cat.No. | Name | Information |
|---|---|---|
| M40697 | NX-5948 | NX-5948 (BTK-IN-24) is an orally active, blood-brain barrier-penetrating, BTK-targeting degradation agent for the study of B-cell malignancies and autoimmune diseases. NX-5948 induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. NX-5948 mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. |
| M10423 | DT2216 | DT2216 is a BCL-XL protein hydrolysis targeting chimera (PROTAC) that ligates and degrades BCL-XL with E3 ubiquitin (E3) ligase. DT2216 is effective against a variety of BCL-XL-dependent leukemias and cancer cells. |
| M10382 | PROTAC SGK3 degrader-1 | PROTAC SGK3 degrader-1 (SGK3-PROTAC1) is a potent SGK3 degrader, it is a PROTAC conjugate of the 308-R SGK inhibitor with the VH032 VHL binding ligand, targeting SGK3. |
| M57181 | CMP98 | CMP98, a PROTAC, is unable to induce degradation of VHL. |
| M57180 | MS8815 | MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. |
| M57179 | TD-802 | TD-802 is an androgen receptor (AR) PROTAC degrader with good microsomal stability. |
| M57178 | ARD-266 | ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. |
| M57177 | GNE-987 | GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. |
| M57175 | PhosTAC7 | PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and Tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). Similar to PROTACs in their ability to induce ternary complexes, PhosTAC7 focuses on recruiting a Ser/Thr phosphatase to a phosphosubstrate to mediate its dephosphorylation. |
| M57174 | SJ995973 | SJ995973 (PROTAC) is a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins. |
| M57173 | ARD-2585 | ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor. |
| M57172 | XF067-68 | XF067-68 is a PROTAC for targeted degradation of WD40 repeat domain protein 5 (WDR5). |
| M57171 | SJF-8240 | SJF-8240 (PROTAC 7) is a proteolysis targeting chimera (PROTAC) degrader. |
| M57170 | dBRD4-BD1 | dBRD4-BD1 is a selective and durable BRD4 degrader with an DC50 value of 280 nM (Dmax=77%). |
| M57169 | SB1-G-187 | SB1-G-187, a PROTAC, is a multi-kinase degrader. |
| M57168 | QC-01–175 | QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. |
| M57167 | XY028-133 | XY028-133 is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK. |
| M57166 | PROTAC-O4I2 | PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). |
| M57165 | FKBP12 PROTAC RC32 | FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. |
| M57164 | PROTAC ERRα Degrader-3 | PROTAC ERRα Degrader-3 is a potent and selective ERRα degrader based on von Hippel-Lindau ligand. |
| M57163 | PROTAC FKBP Degrader-3 | PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an von Hippel-Lindau binding group. |
| M54696 | DGY-09-192 | DGY-09-192 is a bivalent degrader that couples the pan-FGFR inhibitor BGJ398 to the CRL2VHL E3 ligase-recruiting ligand, which induces degradation of FGFR1/2 and largely avoids degradation of FGFR3/4.DGY-09-192 exhibits a nanomolar DC50 against both wild-type FGFR2 and several FGFR2 fusions. In addition, DGY-09-192 has antiproliferative activity in gastric and cholangiocarcinoma cells. |
| M54671 | BTX-6654 | BTX-6654 is a targeted and specific cerebellar-based bifunctional SOS1 PROTAC degrader.BTX-6654 reduces the downstream signaling markers pERK and pS6 and displays antiproliferative activity in a wide range of KRAS-mutant cells. In two KRAS G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
